Recombinant Human SFTPB Protein, N-GST & C-His

Description of Recombinant Human SFTPB Protein, N-GST & C-His

Introduction

Recombinant Human SFTPB Protein, also known as Surfactant Protein B, is a key component of the pulmonary surfactant complex that is essential for proper lung function. This protein is encoded by the SFTPB gene and is primarily produced by type II alveolar cells in the lungs. Recombinant Human SFTPB Protein has been extensively studied and has shown promising results in various applications, making it a valuable tool in the field of respiratory research.

Structure of Recombinant Human SFTPB Protein

Recombinant Human SFTPB Protein is a hydrophobic, 79-amino acid protein with a molecular weight of approximately 8.7 kDa. It is composed of three domains – a hydrophobic N-terminal domain, a hydrophilic central domain, and a hydrophobic C-terminal domain. The N-terminal domain is responsible for the protein’s interaction with phospholipids, while the central domain is involved in the protein’s dimerization. The C-terminal domain is essential for the protein’s proper folding and stability.

Activity of Recombinant Human SFTPB Protein

The primary function of Recombinant Human SFTPB Protein is to reduce surface tension at the air-liquid interface in the lungs, thereby preventing alveolar collapse during expiration. This activity is crucial for proper lung function and gas exchange. Additionally, this protein also plays a role in innate immunity, as it has been shown to have antimicrobial properties. Recombinant Human SFTPB Protein has also been found to have a protective effect against oxidative stress and inflammation in the lungs.

Application of Recombinant Human SFTPB Protein

Research

Recombinant Human SFTPB Protein has been extensively studied in various research areas, including respiratory diseases, lung development, and surfactant biology. Its role in maintaining proper lung function and its potential therapeutic applications make it a valuable tool in respiratory research. Recombinant Human SFTPB Protein has also been used in studies investigating the effects of pollution and other environmental factors on lung health.

Therapeutic Potential

Recombinant Human SFTPB Protein has shown promising results in the treatment of respiratory diseases such as acute respiratory distress syndrome (ARDS) and cystic fibrosis. Studies have shown that supplementation with this protein can improve lung function and reduce inflammation in these conditions. Additionally, Recombinant Human SFTPB Protein has been investigated as a potential therapy for lung injuries caused by radiation or chemotherapy.

Vaccine Development

Recombinant Human SFTPB Protein has also been explored as a potential antigen in vaccine development. It has been shown to induce a strong immune response and has the potential to protect against respiratory infections. This protein has been studied as a potential vaccine candidate against respiratory syncytial virus (RSV) and influenza virus.

Diagnostic Tool

The levels of Recombinant Human SFTPB Protein in the lungs and serum have been found to be altered in various respiratory diseases. This protein has been investigated as a potential biomarker for the diagnosis and monitoring of lung diseases. Its levels can also be used to assess the efficacy of therapeutic interventions.

Conclusion

Recombinant Human SFTPB Protein is a crucial component of the pulmonary surfactant complex and plays a vital role in maintaining proper lung function. Its structure, activity, and potential applications make it a valuable tool in respiratory research and therapeutics. Further studies on this protein’s properties and functions may lead to the development of new treatments for respiratory diseases and improved lung health.